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Quantum Mechanical Studies of DNA and LNA
Troels Koch,1 Irene Shim,2 Morten Lindow,1 Henrik Ørum,1 and Henrik G. Bohr 3
Quantum mechanical (QM) methodology has been employed to study the structure activity relations of DNA
and locked nucleic acid (LNA). The QM calculations provide the basis for construction of molecular structure
and electrostatic surface potentials from molecular orbitals. The topologies of the electrostatic potentials were
compared among model oligonucleotides, and it was observed that small structural modifications induce global
changes in the molecular structure and surface potentials. Since ligand structure and electrostatic potential
complementarity with a receptor is a determinant for the bonding pattern between molecules, minor chemical
modifications may have profound changes in the interaction profiles of oligonucleotides, possibly leading to
changes in pharmacological properties. The QM modeling data can be used to understand earlier observations
of antisense oligonucleotide properties, that is, the observation that small structural changes in oligonucleotide
composition may lead to dramatic shifts in phenotypes. These observations should be taken into account in
future oligonucleotide drug discovery, and by focusing more on non RNA target interactions it should be
possible to utilize the exhibited property diversity of oligonucleotides to produce improved antisense drugs.
Introduction
The Watson-Crick (W/C) recognition motif, thoughfundamentally straightforward, leads and directs even
the most complex biological processes (Watson and Crick,
1953a, 1953b). It is remarkable how this ‘‘digital’’ bonding
motif has been a driver behind numerous applications where
native nucleic acids are used as probes (Trapane and Ts’O,
1994; Dangler, 1996; Demidov and Frank-Kamenetskii,
2004). In addition, the recognition motif has served as a de-
sign basis for chemically modified nucleic acid analogs em-
ployed for highly specific purposes (Uhlmann and Peyman,
1990; Nielsen et al., 1991; Hanvey et al., 1992; Shabarova,
1994;Martin, 1995; Altmann et al., 1996; Corey, 1997; Freier
and Altmann, 1997; Cook, 1999; Uhlmann, 2000; Davis
et al., 2006; Debart et al., 2007; Eckstein, 2007; Koch and
Ørum, 2007; Koch et al., 2008). One of the areas where
nucleic acid analogs have extensively been used is for the
antisense silencing of gene expression (Zamecnik and
Stephenson, 1978). This therapeutic field is based on the
inhibition of RNA expression by oligonucleotide analogs
designed to specifically recognize, by W/C hydrogen bond-
ing, a complementary target sequence (Zamecnik and
Stephenson, 1978).
Over the past 3–4 decades, many nucleic acid analogs
have been produced for antisense purposes (Zamecnik and
Stephenson, 1978; Uhlmann and Peyman, 1990; Martin,
1995; Freir and Altmann, 1997; Uhlmann, 2000; Wengel,
2001; Koch and Ørum, 2007; Koch et al., 2008; Yamamoto
et al., 2011). Despite this extensive work, antisense oligo-
nucleotides have not fully realized their clinical promise.
Only a small fraction of the analogs have ever been clinically
evaluated, and just two antisense drugs have been approved
by the United States Food and Drug Administration for
marketing (KynamroTM and VitraveneTM). Enthusiasm for
antisense therapeutics was renewed when the nucleic acid
analog locked nucleic acid (LNA) was synthesized (Obika
et al., 1997; Singh et al., 1998). LNA represents a class
of bicyclic nucleic acid analogs, and in the parent LNA nu-
cleoside, the furanose ring is chemically modified by inser-
tion of a 2¢-O-CH2-4¢ linkage that transforms the furanose to
the bicyclic structure. When LNA nucleosides are incorpo-
rated into oligonucleotides, the bicyclic modification induces
not only substantially increased nuclease stability, but also
good mismatch discrimination and high hybridization affin-
ity. LNA nucleosides are equally well combined with native
phosphordiester oligonucleotides (PO) or phosphorothioates
(PS) (Cohen, 1993; Eckstein, 2007). Driven by its high af-
finity, LNA has enabled a platform technology for the inhi-
bition of both coding and non-coding RNAs (Wahlestedt
et al., 2000; Jepsen and Wengel, 2004; Hansen et al., 2008;
Koch et al., 2008; Elmen et al., 2008a, 2008b; Seth et al.,
2009; Lanford et al., 2010; Straarup et al., 2010; Lindholm
et al., 2011; Obad et al., 2011).
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However, in contrast to the simplicity of nucleic acid
recognition (W/C), the binding principles are far more
complex between oligonucleotides and other biomolecules.
For instance, it has been reported that small structural mod-
ifications of antisense oligonucleotides (e.g., LNAs) have
profound effects on these relations, which are observed as
property changes. (Seth et al., 2009; Straarup et al., 2010;
Laxton et al., 2011; Stanton et al., 2012). The mechanisms
behind this ‘‘property diversity’’ are not understood, and it is
clear that a reductionist viewpoint, where the complex
properties of a given oligonucleotide (e.g., tissue and cellular
uptake, pharmacokinetics, toxicity) are assigned by a simple
correlation with the nucleobase sequence alone, neither de-
scribes nor predicts these structure/activity changes.
In order to further study the property diversity of oligo-
nucleotides, we have used a methodology employing quan-
tum mechanical calculations (QM). By employing QM
calculations, we have established the electronic orbital con-
figuration of selected model oligonucleotides and, based on
that, have calculated the molecular electrostatic iso-potential
surfaces. These serve as a model for visualizing the three-
dimensional changes in molecular structure and electrostatics
induced by changes in oligonucleotide composition. Mole-
cular structure and electrostatic iso-potential surfaces serve
as models for studying the interaction of oligonucleotides
with non-RNA target biomolecules (i.e. proteins), and altered
patterns should be reflected in global property changes.
The observation of a diversified binding potential of oligo-
nucleotides to non-target molecules can be exploited, and we
suggest that a stronger focus on oligonucleotide/non-target
interactions could be a targeted approach for making antisense
lead candidates with improved pharmacological properties.
Material and Methods
The molecules studied were first constructed ab initio by
adding the atoms or whole nucleotides together with a
phosphor-sugar backbone using the chemical program
SPARTAN ’10 (Wavefunctions, Inc.), or employing the
graphics in Gauss-view. After having built the desired mo-
lecular structure, the molecule is transferred to a Quantum
Mechanical program (e.g. Gaussian program package)
(Frisch, 2009) on a supercomputer where the optimization
procedure can be carried out.
The electronic properties of the oligonucleotides, both with
respect to their molecular orbitals and their electrostatic sur-
faces, were obtained by QM Hartree-Fock (HF) optimization
employing the basis set of Gaussian type functions. In this
approach, a large energy functional can be optimized with re-
spect to the electrostatic energy configuration solely on the
basis of the electronic density by separating electron and nu-
clear motions. Once the energy-minimized electronic structure
is obtained (i.e., the nuclear coordinates and electron orbitals in
the ground state), the electrostatic surfaces and the HOMO
(highest occupied molecular orbital) and LUMO (lowest un-
occupied molecular orbital) bonding system can be calculated,
thus providing information about electron donor/acceptor sites.
More precisely, we employed the Hartree-Fock self-
consistent field (HF SCF) QM method with linear combina-
tion of atomic orbitals approximation applied to the usual
Schr}odinger electronic equation (used together with matrix
equations of the Roothaan Hall type). We selected HF since it
is generally acknowledged that this method provides better
optimization results for large biomolecules due to non-local
interactions and avoidance of empirical parametrization. The
Schro¨dinger electronic equation can be written as:
F Æccoefæ¼E L Æccoefæ
where ccoef are wave function orbital coefficients, E are or-
bital energies, L are overlap terms and F is a so-called Fock
matrix given in terms of a core-electron Hamiltonian (H), the
Coulomb, and Exchange terms such that:
Flv¼Hcorelv þ JlvþKlv:
The core Hamiltonian is derived from the Schro¨dinger
equation with the one electron wavefunction jm:
Hcorelv ¼
Z
ul[ h2=2m)D (e2=4pe0)SZi=r]uv ds
where D stands for the Laplace operator, m is the electronic
mass, e is the electron charge, Zi is the charge of the nucleus i,
and the Coulomb and Exchange potential terms are expanded
on the basis functions. These are here taken as split-valence
basis sets of Gaussian functions denoted as either 6-31G* or
3-21G (less accurate), which describe the number of Gauss-
ian functions in a sum with coefficients. The energies of the
molecular parts with wave functions are used to calculate the
potential energy surface. This represents the electrostatic
potential energy based on wave-function optimization of the
orbital structure from where the effective charges can be
extracted, or in other words, the electrostatic potential energy
a positive test charge is experiencing when approaching the
molecule. It was found convenient to describe this potential
energy by an iso-surface of defined field strength, which was
identical over the entire surface (Bohr, 2013).
In the HF calculation, the lowest energy states are found by
optimization under the constraints of self-consistent (SCF)
field procedures that obey the laws of electrodynamics. The
HF calculations are based on independent particle models
where the electrons experience a mean field from the elec-
trons and the nuclei. In the Density Functional Theory ap-
proach, the exchange potential is based on electron densities,
while the HF method uses wave functions also describing
non-local exchange potentials.
The HF calculations are stepwise processes: Initially,
single stranded molecules were constructed. DNA or LNA
oligonucleotide (nucleobase and sugar-phosphate backbone)
consists of hundreds of atoms. Next, the molecule was sub-
jected to a basic electrostatic optimization to determine if the
molecular structure is stable. Finally, the coordinate file was
transferred to a high performing supercomputer that opti-
mizes the proposed electronic structure using variational
methods, and constructs the electronic orbitals that are con-
sistent with the electrostatic functionals.
The process of proposing a system of wave functions and
checking their consistency according to their electronic
densities is then carried out for many iterations (ca. 1,000)
and is terminated when a convergent state is reached. In a
complete quantum mechanical calculation of a molecular
structure, it is important to include solvent effects on the
140 KOCH ET AL.
naked (gas phase) molecule. Water molecules are here
included indirectly by altering the dielectric constant (relative
permittivity 75) in a cavity. From the electrostatic iso-surfaces,
in addition to charge densities, differential geometric proper-
ties such as topology can also be obtained. These geometric
properties appear in the connectedness of the surface and the
curvature values (see Figs. 1–6).
An important question is which role the initial conditions
play on the quantum electronic structure calculation and
optimization and if changed initial conditions will lead to
different conformational structures. These could be purely
technical initial conditions such as the choice of basis set for
the quantum mechanical optimization. In order to assess the
dependence of the initial conditions of the calculated opti-
mized structures of a given molecule, we chose a DNA
oligomer as a test case. Hence, we calculated optimized
electronic structures of the DNA-7mer of ATGTAGC using
the basis set 3-21G and 6-31G*, where the latter is the double
size of the former: The measure for the difference of the
electronic structures can be the size of the HOMO/LUMO
gap (quantum mechanically) and more classically, the end-
to-end distance of the molecular structure. For the smaller
basis set 3-21G, the HOMO-state is - 0.30787 H and the
LUMO-state is - 0.04727; and thus, the H/L gap is
g = 0.26060. The end-to-end distance is l = 15.75 A˚, measured
between specific atoms separated with long distance (the
exocyclic nitrogen on the 5¢ end adenosine and the 3¢ carbon
of the deoxyribose of the 3¢ end cytosine). For the larger basis
set 6-31G*, the HOMO-state is - 0.31649 and the LUMO-
state - 0.04342, and the gap becomes g= 0.27307. The end-
to-end distance was in this case l = 16.95 A˚. Thus, we see only
little change in the resulting quantum electronic structures,
making the optimized structures more unique. It should be
noted that uniqueness of the quantum electronic structures
are related to calculated minima. In particular for larger
molecules ( > 3nts) more minimized structures exist, but
importantly such other structures and their related MEPs
are specific for the given compound. Altogether, the QM
calculations presented here produce optimized electronic
structures and molecular electrostatic potentials and impor-
tantly, the outcome of QM calculations appear less dependent
on initial conditions than for example, classical molecular
dynamics.
The QM calculation method employed here has been ex-
perimentally verified by spectroscopy studies of other bio-
molecules (peptides). The theoretically derived spectra
required electronic wave functions, and hence QM, in order
to get the quantum states, or wave functions for the matrix
element, of the atomic tensors describing vibrational states. It
was reported in this study that these calculations were in
accordance with experimentally determined vibrational
spectra of bio-molecules obtained by infrared absorption and
RAMAN scattering ( Jalkanen et al., 2001; Abdali et al.,
2002).
In this study we have also included calculations on oli-
gonucleotides containing phosphorothioate (PS) inter-
nucleoside linkage. Sulfur is introduced during chemical
synthesis and replaces one of the non-bridging oxygens.
Since synthesis of PS modifications creates a chiral phos-
phorous, and since these are normally not resolved, antisense
oligonucleotides are diastereomeric mixtures. The number of
diastereoisomers introduced is equal to 2n, where n is the
number of PSs made in the oligonucleotide. PSs play a central
role in the activity of antisense oligonucleotides (AONs). PSs
are more nucleases resistant than native POs and secure that
antisense oligonucleotides designed with DNA nucleotide
segments are nucleolytic stable. Compared with POs, PS
modified oligonucleotides are also better taken up by cells, and
systemically PSs exhibit better tissue distribution and general
pharmacokinetic properties. Due to these properties PSs are
frequently included in AONs (Lebedeva et al., 2000; Uhlmann,
2000; Krutzfeldt et al., 2005; Koch et al., 2008; Lanford et al.,
2010; Stein et al., 2010; Straarup et al., 2010; Koller et al., 2011;
Moschos et al., 2011; Obad et al., 2011; Stanton et al., 2012).
Results
The QM calculated molecular iso-potentials were com-
pared for either native phosphordiester oligonucleotides (PO)
or chemically modified phosphorothioates (PS) (Cohen,
1993; Eckstein, 2007). The value of the iso-potentials was
chosen to be an energy ranging from 10 - 20 kcal/mol. This
value corresponds to the energy of 2–5 H-bonds and char-
acterizes a potential binding to a receptor.
Initially, the effects of modifying the ribose backbone were
examined. DNA-PO-AAG was compared with all LNA-PO-
FIG. 1. Structures and frontier orbitals (red/blue) for (A)DNA
and (B) LNA with the sequence 5¢-AAG-3¢ (5¢ end at bottom
of structure). The electrostatic potential (negative) is shown in
gray and represented by an Iso-potential value of -83kJ/mol.
FIG. 2. Structures and frontier orbitals (red/blue) for LNA
trinucleotides with sequence 5¢-AAG-3¢, chemically modi-
fied by phosphorothioate internucleoside linkages (PS). In
(A), the configuration of PS is RS and in (B) the configu-
ration is SR. The 5¢ end is at the top in A and at the bottom
in B. The electrostatic potential (negative) is shown in gray
and represented by an Iso-potential value of - 83 kJ/mol.
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AAG (Fig. 1). From the structural representation, DNA is
generally more bent while LNA is more stretched. This is
consistent with the more rigid bicyclic structure of LNA
(Obika et al., 1997; Nielsen et al., 2000; Petersen et al., 2000,
2002; Nielsen and Spielmann, 2005; Hughesmann et al.,
2011). When the iso-potential surfaces are added, the surface
of LNA-PO-AAG is constricted and concentrated on the
phosphate backbone face of the molecule. The HOMOorbital
was shifted from the 5¢ adenine in DNA to the 3¢ guanine of
the LNA, while the LUMO orbital resides on the central
adenine in both. Interestingly, the electrostatic potential
of the 3¢ PO in the DNA is weak, much weaker in fact than
for the other phosphate in the trimer, and exhibits a poten-
tial comparable to the lone pairs on the nucleobases—
particularly the 5¢ adenine.
Next, the effects of changed internucleoside linkages and
PS configuration were examined. LNA-PO-AAG (Fig. 1) was
compared with LNA-PS-AAG (with the PSs in the RS con-
figuration) (Fig. 2A). The PS configuration was determined
by assigning the hydrogen to sulfur (S–P single bond). The
LNA-PS-AAG (RS) modification results in a large potential
change and exhibits a more scattered topology compared to
LNA-PO-AAG, with a shift of the electrostatic potential to-
wards the 5¢ end (Figs. 1, 2A). Interestingly, with the PS in the
SR configuration the topology reverts into a coherent struc-
ture resembling the compact form of the PO congener (Figs.
1B, 2B). PS modification also induces changes in the local-
ization of the frontier orbitals. The HOMO-LUMO orbitals
are split between adenine and guanine for LNA-PO-AAG but
the LUMO resides on the central adenines for both PSs, ir-
respective of configuration. Interestingly, the HOMO resides
on sulfur on the PSs in the S configuration.
The effects of changing/mutating a nucleobase were ex-
amined. LNA-PO-AAG was compared with the mutant LNA-
PO-AGG, (Fig. 3). The single nucleotide mutation causes a
shift in the iso-potential from a compact surface for the AAG
sequence (Fig. 3A) to a more scattered surface for the mutant,
AGG sequence, placing a stronger field on 5¢ adenine (Fig.
3B). In addition, the potential for the 3¢ PO is weakened. The
HOMO shifts from the 3¢ guanine to the 5¢-adenine, while the
LUMO is located on the central guanine (Fig. 3A, C).
The effects of increasing the nucleotide sequence from tri-
mer to pentamer were also examined. The potential of the
LNA-PO-AAG is concentrated around the central/and 5¢-
adenosines. Adding two nucleotides (A and C) changes the iso-
potential concentration towards the 3¢ end and leaves the two
5¢-adenines with much less electrostatic density (Fig. 4). The
frontier orbitals also shift from the central adenine and 3¢
guanine in the trimer to the penultimate 5¢ adenine and the 3¢
adenine in the pentamer. Electrostatically, the potential of
the pentamer is unique.
Sequence/topology relations were examined for larger
oligonucleotides. The biologically active LNA-PO-7-mer
(5¢-ATGTAGC-3¢) (Fig. 5A, C) was compared with the sin-
gle base pair mutant (5¢-ATGAAGC-3¢) (Fig. 5B, D) and
with the DNA-PO-ATGTAGC (not shown). The LNA-PO-7-
mer (5¢-ATGTAGC-3¢) (Fig. 5A, C) was originally designed
by Obad et al. (as fully PS modified) to target the seed se-
quence of microRNA (miR)-221 and miR-222 and accord-
ingly, was able to inhibit both microRNAs due to seed
sequence homology (Obad et al., 2011).
The interchange of the central thymine with adenine does
not cause a change in the position of the frontier orbitals. In
both cases, the HOMO orbital is found on the adenine closest
to the 3¢ end and the LUMO is found on the 5¢ adenine.
However, changing the backbone to DNA causes a shift in
both the position and energy of the frontier orbitals. Thus, in
FIG. 3. Structures and fron-
tier orbitals (red/blue) for LNA
tri-nucleotides with sequence
5¢-AAG-3¢ (A) and 5¢-AGG-3¢
(B). The 5¢ end is at the bottom
of the figure. In (C) the HOMO-
LUMO orbitals are explicitly
shown for LNA 5¢-AGG-3¢. The
electrostatic potential (negative)
is shown in gray and rep-
resented by an Iso-potential
value of - 83 kJ/mol.
FIG. 4. Structures and frontier orbitals (red/blue) for (A)
LNA tri-nucleotide with sequence 5¢-AAG-3¢, and (B) LNA
penta-nucleotide with sequence 5¢-AAGAC-3¢. The 5¢ end is
at the bottom in (A) and is at the top in (B). The electrostatic
potential (negative) is shown in gray and represented by an
Iso-potential value of - 83 kJ/mol.
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the DNA oligonucleotide, the HOMO orbital is on the 3¢
cytosine (E = - 8.38 eV), and the LUMO orbital is on the 5¢
adenine (E = - 1.29 eV) (data not shown). The LNA (5¢-
ATGTAGC-3¢) has the HOMO orbital on the adenine closest
to the 3¢ end (E= - 8.04 eV) and the LUMO orbital on 5¢
adenine (E = - 4.55 eV). Thus, the gap is reduced for the
LNA oligonucleotide (DE= - 3.49 eV) compared with the
iso-sequential DNA oligonucleotide (DE = - 7.09 eV).
The molecular structure of the DNA-PO and LNA-PO oli-
gonucleotide with same sequence (5¢-ATGTAGC-3¢) are
very different, with the DNA oligonucleotide being bent
(ca. 90), and the LNA oligonucleotide with a more straight
structure. Correspondingly, the topologies of the electrostatic
potentials are also very different and each unique. Interest-
ingly, the central thymidine/adenosine mutation causes also a
global change in topologies of the two LNA oligonucleotides
(Fig. 5C, D). The topology of the electrostatic potential of the
mutant is more evenly distributed over the molecule with a
weaker negative potential (red). The central mutation also
causes a 3¢ end weakening of the positive potential (yellow)
(Fig. 5C, D).
Finally, a study was also carried out on a LNA-DNA PO 7-
gapmer. The compound has the same nucleotide sequence as
in the parent LNA compound mentioned above (5¢-ATG
TAGC-3¢), but the middle three nucleotides were substituted
with DNA PO nucleotides. The resulting optimized structure
(Fig. 6A) was more compact and bend—almost globular—
and the increased flexibility converged by the DNA nucleo-
tides brought the two LNA ends close to each other. The
HOMO-LUMO gap was DE = - 4.05 eV, and the established
iso-surface had a disrupted or scattered potential surface very
different from the potential of the iso-sequential full LNA 7-
mer (Fig. 6 B). The electronic data on the 7-mers confirm that
there are no particular boundary effects in this study, al-
though it could be anticipated that special boundary effects
on the 3-mers were dominating.
Discussion
The QM data illustrate that small modifications can
profoundly change the structure, polarity and topology of
the molecular electrostatic potential (MEP) of oligonucle-
otides. Introduction of a single base mutation (Figs. 3, 5)
induces global structural and MEP topology changes, as do
oligonucleotide design changes for iso-sequential com-
pounds (Figs. 5, 6). Changing the sugar backbone from
DNA to LNA can lead to strong polarity changes in the
backbone phosphates (Fig. 1). The molecular structure and
MEP may also be different among diastereoisomers of the
same sequence (Fig. 2). As further illustrated in Fig. 4,
structure and MEP topology for any given compound is
unique; structural modifications lead to topologies that
cannot be viewed simply as additions to a precursor struc-
ture. The wave-function representation illustrates that che-
mical modifications influence both structure and MEP, not
only at the site of incorporation, but throughout the entire
molecule.
Molecular structure, MEP strength, and topology are de-
terminants for the interaction with and the binding pattern
between molecules. Generally, ligand-receptor binding pro-
cesses are very complex, the net binding energy is a balance
between molecular structure and MEP on one side and
counteracting desolvation effects on the other (Chong et al.,
1998; Kangas and Tidor, 1999; Sheinerman et al., 2000;
Muzet et al., 2003; Sulea and Purisima, 2003; Burgoyne and
Jackson, 2006; Kraut et al., 2006; Dhimoy et al., 2008, 2013;
Kenny, 2009). Thus, binding cannot be automatically as-
sumed to take place even if perfect structure and MEP
complementarity exists between ligand and receptor. How-
ever, in some systems, ligand-receptor MEP complementar-
ity appears to play a more determinant role for binding to take
place. These receptor-ligand systems are characterized by
FIG. 5. Three-dimensional chemical structures of the
LNA heptanucleotides (A) 5¢-ATGTAGC-3¢ and (B) 5¢-AT
GAAGC-3¢. The 5¢ end is placed to the right. The topology
of the electrostatic potentials of the two heptanucleotides is
shown in (C) 5¢-ATGTAGC-3¢ and (D) 5¢-ATGAAGC-3¢.
The energy of the electrostatic iso-potential surfaces is set to
1.63 eV (157 kJ/mol). The negative potential is marked with
red and the positive with yellow. The 5¢ end is to the right.
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ligand binding to concave pockets of a receptor where
binding is driven thermodynamically by hydrogen bonding
(Kangas and Tidor, 1999; Muzet et al., 2003). This has
importance for oligonucleotide–protein binding. Oligonu-
cleotide binding proteins usually share a common concave
structure called the OB (oligonucleotide binding) fold (Sun
and Shamoo, 2003; Harris et al., 2012). Oligonucleotide
binding to the fold is driven by hydrogen (H)-bonding which
is further stabilized by hydrophobic interactions and
stacking between nucleobases and aromatic amino acids.
Interestingly, strong binding is also observed to negatively
charged proteins, and the charged backbone may also in-
teract either via H-bonding or salt bridge formation. No-
tably, however, the phosphates are predominately exposed
to the highly dielectric solvent (Max et al., 2006; Zeeb et al.,
2006). The fact that any energy strength can be selected as
an iso-value for the electrostatic potentials (e.g., fixed to H-
bonding energies) means that the MEPs are informative
about how well H-bonding may occur locally. Altogether, it
can be assumed that electrostatic complementarity plays a
more determinant role for single stranded oligonucleotide–
protein interactions.
The interaction/binding of oligonucleotides to proteins is an
important parameter influencing toxicity, plasma half-life,
tissue accumulation, cellular uptake, and activity of antisense
oligonucleotides (Beltinger et al., 1995; Prakash et al., 2002;
Watanabe et al., 2006; Lai et al., 2007a, 2007b; Stein et al.,
2009). Since H-bonding to folded protein structures (e.g., OB
fold) is important for oligonucleotide–protein binding we can
assume that structural and MEP complementarity are deter-
minants for binding/interaction to take place. Consequently,
oligonucleotides with marked differences in MEP are likely to
exhibit differences in protein binding. Assisted by the QM
data, it is evident that small structural modifications may lead
to profound changes in the binding/interaction profile (i.e., the
phenotypic profile). As an example, a single nucleotide mod-
ification (e.g., perfect match vs. one base pair mismatch) may
lead to major, or ‘‘all or none,’’ phenotypic changes. The QM
modeling data explains and illustrates reasons underlying
some of the unexpected observations relating to major phe-
notypic changes observed for otherwise ‘‘closely related’’
molecules (vide infra) (Seth et al., 2009; Straarup et al., 2010;
Laxton et al., 2011; Stanton et al., 2012; Hagedorn et al., 2013).
The data also underlines that caution should be taken in
making broad predictions about the effects of particular
chemical modifications. For instance, in nearly all cases,
incorporation of LNA nucleotides will lead to higher affinity
and nuclease stability. However, how a single LNA modifi-
cation, or other structural units for that matter, will influence
the global effects, on a cellular or systemic level is more
complex. As an example of how the global bioproperties of
LNA gapmer phosphorothioate oligonucleotides can be af-
fected by seemingly minimal changes, a series of these 16-
mer oligonucleotides, targeted to Bcl-2, were synthesized
that differed only by a single base in the gap. After gymnotic
delivery of the oligos to 518A2 cells (Soifer et al., 2012; Stein
et al., 2010), the phosphorylation patterns of the PI3K/Akt/
mTor pathway were examined. Each oligo silenced Bcl-2
protein expression to the same extent. However, the levels of
phosphorylation of PI3K, Akt, and mTOR were different for
every oligo (Cy A. Stein, personal communication). Another
example was recently reported where a specific LNA 13-mer
was hepatotoxic. However, adding just a single additional
LNA nt rendered the resulting 14-mer non-hepatotoxic
(Hagedorn et al., 2013). This demonstrates that single-nu-
cleotide substitutions may induce major phenotypic chan-
ges—changes that are not ‘‘inherited’’ from the single
nucleotide per se, but result more likely from the nucleotide
insertion/substitution in a specific sequence/compound con-
text. At this point in time, we can predict some effects of
single-nucleotide substitutions, but not how single-nucleo-
tide modifications will alter the global interactions. In prac-
tice, this also means that caution should be taken in over-
generalizing about data arising from comparative studies
using single base pair mismatch control oligonucleotides.
The potential to produce very different phenotype, induced
by the single-nucleotide modification compared to the ‘‘full
match’’ oligonucleotide, may be so great that any observed
differences in effects may be caused by the altered global
interaction profile, and only minimally resulting from the
mismatch hybridization effect with the RNA target.
Antisense oligonucleotides are composed of many discrete
structural units each bringing unique properties (e.g., nu-
cleobases, PO/PS internucleotide linkages, DNA/RNA/LNA
backbones, base sequence motifs, etc.). These units collec-
tively engender, in a sequence context, the properties of the
FIG. 6. Three-dimensional
chemical structure of the
LNA-DNA PO gap-mer 5¢-
ATGTAGC-3¢ (LNA nts un-
derlined) (A), and in (B) the
electrostatic potential rep-
resented by an iso-surface
value of iso= 0.06H = 1.62
eV = 156 kJ/mol. The posi-
tive electrostatic potential is
shown in yellow and the
negative in red.
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individual molecule. The QM data shown here illustrate that
each structural element, and potentially their diastereoiso-
mers (Fig. 3), may induce property changes if substituted by
another structural element. This large property diversity
points to the existence of a wide ‘‘property space’’ of oli-
gonucleotides (Koch, 2013). It should be possible to exploit
this understanding in antisense drug discovery by testing
many combinations of a structural units, with the aim to
explore the property space, to be able to select better candi-
dates with unique/extreme properties (Fig. 7). For instance,
optimized lead candidates should exhibit an averaged opti-
mal interaction profile for the global interaction determinant
for effective cellular uptake, efficient intracellular traffick-
ing, low toxicity, and for potent inhibition of the target RNA.
The question is then how large should the oligonucleotide
pool be and how many structural units—pharmacophores—
should be combined? We are not able to answer that question
now, and numbers becomes quickly a limiting factor. For
example, the number of unique 14-mers constructed from 4
different nucleotide building blocks is 414 (2.7 · 108). If the
number of building blocks is increased by adding 4 extra
nucleotides (e.g., four LNA and four DNA nucleotides) an
expanded property space will be formed. However, in order
to explore all combinations 814 = 4.4 · 1012 compounds
would have to be tested. Numbers like these are known issues
from classical small molecule drug discovery and cannot be
managed in practice. Nevertheless, in contrast to small
molecule drug discovery, antisense offers a great advantage:
The RNA-target binding motif is known! Due to the re-
quirement of complementary base pairing to the target, the
relevant compound number is immediately reduced by *6
orders of magnitude (depending on the length and number of
modifications considered). This reduces but still leaves too
many compounds to handle, further reduction required. In
this case, property prediction algorithms are the preferred
tools, and although the QM data illustrate a more intricate
structure/activity relationship of oligonucleotides, it is far
from chaotic. However, new and improved prediction algo-
rithms must be constructed from larger training data sets,
where the property of interest has been measured experi-
mentally, and correlated with several structural entities. These
include nucleobase sequence, backbone, inter-nucleotide
linkages, or any modification of these in combination and
related to a specific molecular context. We are currently
establishing such large databases of thousands of oligonu-
cleotides tested both in vitro and in vivo. A simplified de-
composition of oligonucleotides has been developed,
combined with a random forest classification that with
*80% significance can predict the hepatotoxic potential of
LNA/DNA-gapmer oligonucleotides (Hagedorn et al., 2013).
Predicted experimental outcome by in silico algorithms is
linked with uncertainty. Nevertheless, they offer a knowledge
based strategy to reduce the relevant compound number, by
zooming in on the selection of oligonucleotides where the
probability is highest for finding unique/extreme properties
(Fig. 7). It is therefore not necessary to test all combinations
of a structural unit selection. Testing much smaller numbers
(e.g., 102–104), may be suffice for a thorough investigation of
the property space.
The data presented here are based on QM calculations for
3-, 5-, and 7-mer oligonucleotides; these lengths are signifi-
cantly shorter than the ones used for antisense purposes (12-
to 16-mers). It is therefore relevant to ask if the structural and
MEP sensitivity to the chemical modifications observed here
also is the case for the 12- to 16-mers. We have not yet been
able to complete QM calculations on longer oligonucleotides
because such calculations are very CPU demanding. How-
ever, experimental observations of large property diversity
and the ‘‘all or none’’ phenotypes of closely related antisense
compounds (vide supra) could indicate that single modifi-
cations may affect not only the site of substitution, but can
affect the entire molecule as well. In that case, a wave
function representation could be useful, and accordingly
large variations in structure and MEP would also be expected
for longer oligonucleotides.
Conclusion
The QM oligonucleotide modeling illustrates that structure
activity relations are complex interrelations of individual
chemical components and their specific structural position.
Property diversity is mechanistically driven by the molecular
structure and the derived molecular electrostatic potentials.
Nucleobase sequence is not the only determinant for oligo-
nucleotide properties; the global properties are derived from
each structural unit in concert with the molecular composi-
tion. The diversified recognition potential between oligonu-
cleotides and non-target biomolecules should be exploited.
This could be done by testing more combinations of selected
structural units. In a targeted approach, the binding/interac-
tions between lead compounds and non-target biomolecules
should be optimized together with target RNA inhibition.
FIG. 7. Illustration of ‘‘extreme
properties’’ of drug candidates.
Most oligonucleotides tend to
cluster around a central value for
each variable (phenotype) in
search. The dashed circles illustrate
the atypical and extreme properties
that are selected for in drug dis-
covery: high pharmacological ac-
tivity combined with low toxicity.
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